Figure 2
Relevance of functional p53 for the YM155-mediated anti-neuroblastoma effects. (a) Protein levels of p53, p21, γH2AX, H2AX, phosphorylated Chk2 (pChk2), Chk2, cleaved PARP (cl. PARP), Mcl-1, cIAP-1, cIAP-2, XIAP, and survivin after YM155 (25 nM) treatment for 24 h of non-transduced UKF-NB-3/UKF-NB-6 cells (Control), UKF-NB-3/UKF-NB-6 cells transduced with a lentiviral vector encoding for shRNA targeting p53 (p53 shRNA), or UKF-NB-3/UKF-NB-6 cells transduced by a control vector encoding for non-targeting (‘scrambled’) shRNA (scr shRNA); β-actin served as loading control. (b) YM155 concentrations that reduce neuroblastoma cell viability by 50% (IC50) in UKF-NB-3 and UKF-NB-6 cells in the absence or presence of functional p53; p53 was depleted using a lentiviral vector encoding for shRNA targeting p53 (UKF-NB-3p53shRNA and UKF-NB-6p53shRNA). Numerical values and control cell lines transduced with non-targeting shRNA are presented in Supplementary Table 4. *P<0.05 relative to the respective non-transduced cell
